Phaseline

Targets › TRBV9

TRBV9 (T cell receptor beta variable 9): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Immunology; next expected readout Jun 2027.

V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, A0A0B4J1U6)

Open in Phaseline: the race on TRBV9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiocadBCD-180
anti-TRBV9 monoclonal antibody
TRBV9Phase 3Axial SpondyloarthritisJun 2027

Conditions

Axial Spondyloarthritis (2)

Modalities

antibody (1)

Companies

Biocad (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.